Skip to main content

Table 2 Adverse events

From: Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study

NCI-CTC grade (ver.5)

CBDCA + GEM (n = 65)

CDDP + VNR (n = 17)

 

G1/2 (%)

G3/4 (%)

total

G1/G2 (%)

G3/4 (%)

total

P

Hematological event

 White blood cell decreased

21 (32.3)

0

21 (32.3)

6 (35.2)

0

6 (35.2)

0.925

 Neutropenia

18 (27.6)

10 (15.3)

28 (43.0)

3 (17.6)

8(47.0)

11 (64.7)

0.002*

 Thrombocytopenia

21 (32.2)

3 (4.6)

24 (36.9)

2 (11.7)

0

2 (11.7)

0.377

 Anemia

5 (7.6)

0

5 (7.6)

1 (5.8)

0

1 (5.8)

0.076

 Febrile neutropenia

0

0

0

0

0

0

 

Non-hematological event

 Nausea

5 (7.6)

0

5 (7.6)

10 (58.8)

2(11.7)

1 2(70.5)

< 0.001*

 Anorexia

5 (7.6)

0

5 (7.6)

6 (35.2)

3(17.6)

9 (52.9)

< 0.001*

 Mucositis oral

2 (3.0)

0

2 (3.0)

0

0

0

0.464

 Fatigue

7 (10.7)

0

7 (10.7)

7 (41.1)

0

7 (41.1)

0.045*

 AST increased

5 (7.6)

0

5 (7.6)

1 (5.8)

0

1 (5.8)

0.798

 ALT increased

10 (15.3)

0

10 (15.3)

3 (17.6)

0

3 (17.6)

0.272

 Creatinine increased

2 (3.0)

0

2 (3.0)

2 (11.7)

0

2 (11.7)

0.121

 Constipation

14 (21.5)

0

14 (21.5)

2 (11.7)

0

2 (11.7)

0.631

 Diarrhea

1 (1.5)

0

1 (1.5)

0

0

0

0.606

 Pneumonitis

1 (1.5)

0

1 (1.5)

0

1(5.8)

1 (5.8)

0.128

 Infection

1 (1.5)

0

1 (1.5)

0

0

0

0.606

 Rash

3 (4.6)

0

3 (4.6)

0

0

0

0.665

 Hypophosphatemia

1 (1.5)

0

1 (1.5)

0

0

0

0.606

 Vertigo

2 (3.0)

0

2 (3.0)

1 (5.8)

0

1 (5.8)

0.583

 Insomnia

1 (1.5)

0

1 (1.5)

0

0

0

0.606

 Alopecia

1 (1.5)

0

1 (1.5)

0

0

0

0.606

 Peripheral nerve disorder

1 (1.5)

0

1 (1.5)

0

0

0

0.606

 Supraventricular tachycardia

0

1 (1.5)

1 (1.5)

0

0

0

0.606

 Vasculitis

0

0

0

5 (29.4)

0

5 (29.4)

< 0.001*

  1. *P < 0.05